JP Morgan Chase’s Tempest Therapeutics TPST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5
| Closed | -$8 | – | 8086 |
|
|
2026
Q1 | $8 | Buy |
+5
| New | +$12 | ﹤0.01% | 7445 |
|
|
2025
Q2 | – | Sell |
-6
| Closed | -$57 | – | 7647 |
|
|
2025
Q1 | $57 | Buy |
+6
| New | +$68 | ﹤0.01% | 6962 |
|
|
2024
Q1 | – | Sell |
-8
| Closed | -$484 | – | 7888 |
|
|
2023
Q4 | $484 | Buy |
+8
| New | +$379 | ﹤0.01% | 6933 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 7411 |
|
|
2023
Q2 | – | Sell |
-24
| Closed | -$1K | – | 7335 |
|
|
2023
Q1 | $1K | Buy |
+24
| New | +$526 | ﹤0.01% | 6555 |
|
|
2022
Q2 | – | Sell |
-10
| Closed | – | – | 6896 |
|
|
2022
Q1 | $0 | Buy |
+10
| New | +$454 | ﹤0.01% | 7025 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 6804 |
|
|
2021
Q2 | $0 | Buy |
+1
| New | +$225 | ﹤0.01% | 6616 |
|
|
2021
Q1 | – | Sell |
-386
| Closed | -$156K | – | 6356 |
|
|
2020
Q4 | $161K | Buy |
386
+381
| +7,620% | +$132K | ﹤0.01% | 4878 |
|
|
2020
Q3 | $1K | Sell |
5
-15
| -75% | -$5.09K | ﹤0.01% | 5419 |
|
|
2020
Q2 | $7K | Sell |
20
-159
| -89% | -$63.4K | ﹤0.01% | 5162 |
|
|
2020
Q1 | $185K | Buy |
179
+42
| +31% | +$61.3K | ﹤0.01% | 4301 |
|
|
2019
Q4 | $180K | Buy |
137
+121
| +756% | +$171K | ﹤0.01% | 4713 |
|
|
2019
Q3 | $22K | Buy |
16
+3
| +23% | +$4.84K | ﹤0.01% | 5396 |
|
|
2019
Q2 | $29K | Buy |
13
+10
| +333% | +$29.4K | ﹤0.01% | 5367 |
|
|
2019
Q1 | $10K | Buy |
3
+2
| +200% | +$4.42K | ﹤0.01% | 5544 |
|
|
2018
Q4 | $1K | Hold |
1
| – | – | ﹤0.01% | 5633 |
|
|
2018
Q3 | $2K | Hold |
1
| – | – | ﹤0.01% | 5615 |
|
|
2018
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 5468 |
|
|
2018
Q1 | $3K | Sell |
1
-30
| -97% | -$89.9K | ﹤0.01% | 5269 |
|
|
2017
Q4 | $127K | Buy |
+31
| New | +$130K | ﹤0.01% | 4575 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 5187 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 5220 |
|
|
2016
Q4 | – | Hold |
0
| – | -$9K | – | 5131 |
|
|
2016
Q3 | – | Sell |
-127
| Closed | -$2.3M | – | 4314 |
|
|
2016
Q2 | $1.94M | Buy |
127
+10
| +9% | +$228K | ﹤0.01% | 2824 |
|
|
2016
Q1 | $3.24M | Buy |
117
+3
| +3% | +$63.4K | ﹤0.01% | 2446 |
|
|
2015
Q4 | $3.25M | Buy |
114
+5
| +5% | +$165K | ﹤0.01% | 2482 |
|
|
2015
Q3 | $2.72M | Buy |
109
+35
| +47% | +$2.36M | ﹤0.01% | 2593 |
|
|
2015
Q2 | $6.28M | Sell |
74
-1
| -1% | -$91.6K | ﹤0.01% | 2256 |
|
|
2015
Q1 | $7.59M | Buy |
75
+20
| +36% | +$2.66M | ﹤0.01% | 2072 |
|
|
2014
Q4 | $7.09M | Buy |
+55
| New | +$4.03M | ﹤0.01% | 2176 |
|
|
2014
Q1 | – | Sell |
-77
| Closed | -$2.06M | – | 3929 |
|
|
2013
Q4 | $2.06M | Sell |
77
-42
| -35% | -$1.15M | ﹤0.01% | 2736 |
|
|
2013
Q3 | $3.45M | Buy |
+119
| New | +$4.22M | ﹤0.01% | 2433 |
|
Other funds holding TPST
SM
VVM
JP Morgan Chase's TPST Position: Q2 2026 in Review
JP Morgan Chase sold out of Tempest Therapeutics (TPST) in Q2 2026, closing a stake of 5 shares — an estimated $8 sold.
JP Morgan Chase first reported a position in TPST in Q3 2013 and held it in 28 quarters. The position peaked at $7.59M in Q1 2015. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.
- JP Morgan Chase reported no remaining Tempest Therapeutics position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 5 Tempest Therapeutics shares in Q2 2026, an estimated $8.
- JP Morgan Chase first reported a position in Tempest Therapeutics in Q3 2013 and held it in 28 quarters.
- JP Morgan Chase's Tempest Therapeutics position peaked at $7.59M in Q1 2015.
- 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.